MARKET

GNMX

Aevi Genomic Med
GNMX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.3309
-
-3.1067
12,892,716.43
Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%
Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody
Seekingalpha · 03/29/2021 11:14
CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
Zacks Small Cap Research · 12/13/2019 14:50
Cerecor To Acquire Aevi Genomic Medicine For $16.1M In An All-Stock Transaction
Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered
Benzinga · 12/05/2019 13:49
The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Oct. 16.)
Benzinga · 10/17/2019 11:39
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 87 companies achieved new lows for the year.
Benzinga · 10/16/2019 14:55
The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 7)
Benzinga · 10/08/2019 11:11
The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.)
Benzinga · 10/01/2019 12:10
No Data
Learn about the latest financial forecast of GNMX. Analyze the recent business situations of Aevi Genomic Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GNMX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 0.1659
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q1 2019
Institutional Holdings
Institutions: 33
Institutional Holdings: 4.96M
% Owned: 6.38%
Shares Outstanding: 77.71M
TypeInstitutionsShares
Increased
3
1.43M
New
6
137.62K
Decreased
7
587.98K
Sold Out
3
378.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman
Sol Barer
President/Chief Executive Officer/Director
Michael Cola
Chief Financial Officer
Michael McInaw
Chief Scientific Officer
Garry Neil
Director
Matthew Bayley
Independent Director
Eugene Bauer
Independent Director
Alastair Clemow
Independent Director
Barbara Duncan
Independent Director
Joseph Grano
No Data
No Data

Webull offers kinds of Aevi Genomic Med stock information, including NASDAQ:GNMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMX stock methods without spending real money on the virtual paper trading platform.